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(INEB), and 5Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal. 6Center for RNA 
Interference and Non-coding RNAs, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. 7Research 
Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy Iuliu 
Hatieganu, Cluj-Napoca, Romania. 8Department of Functional Genomics, The Oncology Institute, Cluj-Napoca, Romania. 
9Molecular Morphology Laboratory, Department of Investigative Pathology, AC Camargo Cancer Center, São Paulo, Brazil. 
10Hereditary Cancer Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet 
de Llobregat, Barcelona, Spain. 11Mayagüez Campus, University of Puerto Rico, Mayagüez, Puerto Rico, USA. 12University 
of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, USA. 13Department of Surgery, Fundeni Hospital, Carol 
Davila University of Medicine and Pharmacy, Bucharest, Romania. 14Rio Piedras Campus, University of Puerto Rico, 
San Juan, Puerto Rico, USA. 15Department of Pediatrics, MD Anderson Cancer Center, The University of Texas, Houston, 
Texas, USA. 16Department of Pathology, Health Sciences Center, University of Oklahoma, Oklahoma City, Oklahoma, USA. 
17Department of Epigenetics and Molecular Carcinogenesis and 18Center for Cancer Epigenetics, MD Anderson Cancer 
Center, The University of Texas, Houston, Texas, USA. 19Department of Hematology, The Oncology Institute Ion Chiricuta, 
University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by cytopenia and extramedullary 
hematopoiesis, resulting in splenomegaly. Multiple pathological mechanisms (e.g., circulating 
cytokines and genetic alterations, such as JAKV617F mutation) have been implicated in the etiology 
of MF, but the molecular mechanism causing resistance to JAK2V617F inhibitor therapy remains 
unknown. Among MF patients who were treated with the JAK inhibitor ruxolitinib, we compared 
noncoding RNA profiles of ruxolitinib therapy responders versus nonresponders and found 
miR-543 was significantly upregulated in nonresponders. We validated these findings by reverse 
transcription–quantitative PCR. in this same cohort, in 2 additional independent MF patient cohorts 
from the United States and Romania, and in a JAK2V617F mouse model of MF. Both in vitro and in vivo 
models were used to determine the underlying molecular mechanism of miR-543 in MF. Here, we 
demonstrate that miR-543 targets the dioxygenases ten-eleven translocation 1 (TET1) and 2 (TET2) 
in patients and in vitro, causing increased levels of global 5-methylcytosine, while decreasing the 
acetylation of histone 3, STAT3, and tumor protein p53. Mechanistically, we found that activation 
of STAT3 by JAKs epigenetically controls miR-543 expression via binding the promoter region of 
miR-543. Furthermore, miR-543 upregulation promotes the expression of genes related to drug 
metabolism, including CYP3A4, which is involved in ruxolitinib metabolism. Our findings suggest 
miR-543 as a potentially novel biomarker for the prognosis of MF patients with a high risk of 
treatment resistance and as a potentially new target for the development of new treatment options.
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Introduction
Myelofibrosis (MF) is a hematological malignancy characterized by the expansion of  a myeloid neoplastic 
clone, leading to progressive bone marrow (BM) fibrosis with cytopenia and extramedullary hematopoiesis 
(1). The most prominent pathological feature in MF is the BM fibrosis. BM fibrosis leads to the deposi-
tion of  reticulin or collagen fibers that create fibrous scar-like tissue (1), and the extent of  BM fibrosis in 
MF patients has been correlated with clinical manifestations of  advanced disease, together with a worse 
prognosis (1, 2). Inadequate production of  blood cells (anemia, thrombocytopenia), bone pain, weakness 
and fatigue, a high risk of  infection and bleeding, night sweats, and progressive spleen enlargement are all 
characteristics of  advanced MF. Patients with MF have a median survival of  4–7 years (3, 4) and an overall 
median survival of  5.75 years after diagnosis (5).
Somatic mutations in genes such as JAK2 (specific mutation at JAK2V617F in 50%–60% of  patients), MPL 
(thrombopoietin receptor; specific mutation at MPLW515L/K in 5%–10% of  patients), and CALR (calreticu-
lin; specific mutation at exon 9 in 20%–30% of  patients), among others, have been identified in patients 
with MF (6–11). These mutations directly result in the constitutive activation of  the JAK/STAT pathway. 
The JAK1/2 tyrosine kinase inhibitor ruxolitinib, the only FDA-approved therapy for MF, significantly 
improves splenomegaly and patients’ quality of  life. However, ruxolitinib does not eliminate BM fibrosis, 
nor does it eradicate neoplastic clones (12), indicating that other pathogenic players need to be discovered 
and therapeutically exploited. Currently, allogeneic stem cell transplantation is the only curative therapy. 
However, fewer than 10% of  patients are eligible and treatment-related mortality is common (13). There-
fore, novel and effective therapies are needed posthaste.
MicroRNAs (miRNAs) are small, noncoding RNAs with regulatory functions that play a significant 
role in many human diseases, including cancer (14–20). Emerging studies show that miRNAs can act either 
as oncogenes or as tumor suppressor genes or sometimes as both (21, 22). Profiling of  miRNA expression, 
both in tissues or circulating biofluids, has enabled advancements in diagnostics, disease staging, monitor-
ing of  disease progression, prognosis, and the evaluation of  treatment response of  various cancers and dis-
eases (23–26). Moreover, miRNAs are proved to have important regulatory roles in hematopoiesis (27–32).
In this study, we hypothesized that response to ruxolitinib is related to deregulated miRNA expres-
sion. Therefore, miRNAs could represent one of  the missing links for deciphering the mechanism of  
resistance to ruxolitinib therapy in MF (33). Here, we evaluated a cohort of  107 patients with MF who 
were treated with ruxolitinib at our center as a part of  a phase I–II study and stratified them according 
to whether they had complete elimination of  palpable splenomegaly (“responders”) or had less than 
25% reduction in spleen size (“nonresponders”) (34, 35). By profiling the expression of  miRNAs, we 
found the miR-543 cluster on chromosome 14q and the miR-182 cluster on chromosome 7q are dereg-
ulated. Notably, we found that miR-543 acts by targeting the epigenetic regulators ten-eleven translo-
cation 1 (TET1) and 2 (TET2), which are members of  a family of  proteins that play a direct role in the 
DNA methylation process and gene activation and an indirect role in protein acetylation. We further 
identified that activation of  STAT3 by the phosphorylation of  JAK2 influences miR-543 transcription 
through its direct binding to miR-543 promoter.
Results
Genome-wide expression profiles of  specific miRNAs stratify MF patients according to their responsiveness to ruxoli-
tinib treatment. Because miRNAs have been widely explored to assess their clinical value as markers of  
cancer progression and treatment effectiveness (36), we analyzed the expression of  miRNAs in patients 
with MF treated with ruxolitinib. From a study population of  107 patients with MF treated with ruxoli-
tinib, we focused on the 2 extreme groups: the “responders” (n = 15, with complete elimination of  palpa-
ble splenomegaly) and the “nonresponders” (n = 12, with 0%–24% spleen size reduction) to ruxolitinib 
treatment. We rationalized that by analyzing only these opposite groups and eliminating the patients with 
intermediate benefit, we would be able to identify the functionally most important miRNAs from the 
many differentially expressed ones in response to ruxolitinib. The disease progression of  these patients 
was monitored for up to 4 years. The clinical features of  the patients with MF in this study are described in 
Table 1. To identify the miRNAs differentially expressed between the 2 groups, we selected 7 patients from 
each group that had sufficient high-quality RNA available and performed Affymetrix miRNA microarrays 
for baseline (before the start of  the treatment) BM samples. The analysis revealed that 227 miRNAs were 
significantly downregulated, while 164 were upregulated in the nonresponders (P < 0.05). Among these, 
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we selected the miRNAs that had at least 2.5-fold difference relative to the responders and a P value less 
than 0.01 (8 downregulated miRNAs and 15 upregulated miRNAs; Figure 1A) for further validation with 
reverse transcription–quantitative PCR (RT-qPCR).
Differentially expressed miRNAs between patients with MF who responded or did not respond to ruxolitinib 
treatment. The differential expression of  miR-543, miR-382, miR-182, and miR-183 was then support-
ed, by RT-qPCR, in the extended group (n = 27) of  samples of  responders and nonresponders, includ-
ing the 14 tested by microarray. Our results showed that miR-543 (Figure 1B) and miR-382 (Supple-
mental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.121781DS1) were significantly upregulated in nonresponders (n = 12) versus responders (n = 15) 
(cohort 1), whereas miR-182 and miR-183 were significantly downregulated (Supplemental Figure 1, B 
and C). When analyzing miR-543 expression profiling for the available patients with MF developed from 
essential thrombocythemia (ET) or polycythemia vera (PV), we found no statistical difference in the num-
ber of  responders (2 with previous PV and 4 with previous ET) versus nonresponders (4 with previous PV) 
(data not shown). Because miR-182 and miR-183 belong to the miR-96/182/183 cluster located within 
the 5-kb region on human chromosome 7q32.2, we tested the expression of  miR-96 also and found it to 
be significantly downregulated in nonresponders also (Supplemental Figure 1D). miR-382 is part of  the 
miRNA cluster B at 14q32, encompassing 42 miRNAs, out of  which 15 were identified by the array as dif-
ferentially expressed between the 2 groups. Overall, we identified miR-543 and miR-382 to be significantly 
overexpressed, while miR-96, miR-182, and miR-183 were significantly decreased in nonresponders when 
compared with ruxolitinib treatment responders.
Lower connectivity of  the miRNA network is present in responders to ruxolitinib. As a second approach for 
identifying the functionally most relevant miRNAs among the 23 found to be differentially expressed by 
microarray, we built an expression network for these miRNAs (37). This represents a high-level correlation 
between the miRNA expression in a given group of  patients and is composed of  nodes (the miRNAs) 
and of  edges (high correlations between the expression of  2 miRNAs) (38, 39). The miRNA network of  
nonresponders is far more connected compared with responders (Figure 1C): it contains 104 edges, being a 
well-connected network with 14 nodes with over 10 edges each (nodes with high node connectivity, 0.4783–
0.6087). On the other hand, responders’ miRNA network is a less connected network, with 57 edges and a 
lower node connectivity at 0.4783. This network contains 6 isolated nodes and 2 other nodes that are linked 
only to each other (miR-485 and miR-543). The hubs of  responders’ network have a lower number of  con-
nections compared with the hubs of  nonresponders’ network. The connectivity of  the nodes of  responders 
network was significantly lower compared with nonresponders network (P = 0.0137; Supplemental Figure 
2). When analyzing the behavior of  single miRNA nodes, we observed that a group of  miRNAs with low 
connectivity in responders’ network (0 edges or 1 edge) are key elements of  the nonresponders’ network, 
containing 14 edges each with an increase in the node connectivity. The miRNAs that showed the highest 
increase in the number of  edges between the 2 groups are miR-100 and miR-134, with 14 edges in the non-
responders’ network, and miR-543 and miR-487a, with 13 edges. We can conclude that response to treat-
ment implies a dramatic reorganization of  the miRNA network, with the exclusion of  6 important nodes 
having a marked decrease in the number of  edges. Very interestingly, a different research group also used 
miRNA microarray expression data with in silico target prediction data to build miRNA-gene networks for 
primary MF and identified miR-543 as the most connected node of  the network (40).
Because our interest was specifically to establish why certain patients do not respond to the ruxolitinib 
therapy, and the only miRNA in common between the confirmed significantly differentially expressed genes 
and the network analysis studying the most network connected miRNAs independently of  the expression 
was miR-543, as a potentially key element of  the nonresponder’s miRNA network, we directed our focus 
toward the overexpression of  miR-543.
miR-543 is overexpressed in MF samples from independent cohorts of  patients. We next assessed the expression of  
miR-543 in BM cells derived from patients with MF in comparison with BM cells from healthy individuals. 
We observed that this miRNA was significantly overexpressed in an independent MF patient cohort (cohort 
2) when compared with healthy controls (Figure 1D and Supplemental Table 1). Similar results were obtained 
when measuring the expression levels of miR-543 in an independent cohort (cohort 3) (Figure 1E and Supple-
mental Tables 1 and 2). Furthermore, we analyzed the publicly available data sets (41) (microarray GSE53482) 
of CD34+ cells from primary MF (n = 42) and healthy donors (n = 31) and detected a significant overexpres-
sion of miR-543 in CD34+ cells from patients with MF (Supplemental Figure 3A). Survival analysis showed a 
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trend of lower overall survival in MF patients with high miR-543 levels compared with those with low levels 
(Supplemental Figure 3B). Taken together, these data from multiple sets of patients from different institutions 
confirm that miR-543 is overexpressed in MF, with the highest expression in nonresponders to ruxolitinib.
Functional role of  miR-543 in transcriptomic profile. To determine the role of  miR-543 in MF, we per-
formed target prediction of  the miRNA binding sites using multiple algorithms (9 algorithms as described 
in the Methods section) and selected those that were strongly predicted (at least in 6/9 algorithms) or 
experimentally validated (regardless of  the target prediction results) using miRTarBase database. Pathway 
analyses of  the miR-543 predicted targets are shown in Supplemental Table 3.
In the absence of  established MF cell lines, we generated K562 (human chronic myelogenous leu-
kemia) and OCI-AML3 (human acute myeloid leukemia) cells with stable overexpression of  miR-543 
(Supplemental Figure 4, A and B) to study the role of  miR-543 in MF in vitro. Enrichment analysis of  
gene expression microarrays (GEMs) of  K562 cells overexpressing miR-543 showed that the enrich-
ment of  selected miR-543 target genes is reduced as expected (Figure 2A, and Supplemental Table 4). 
Interestingly, overexpression of  miR-543 promotes an increased enrichment of  genes related to drug 
and xenobiotic metabolism and a decreased enrichment of  genes related to DNA replication and to 
G2/M checkpoint (Figure 2A and Supplemental Tables 5–7). Using the available RNA samples from 
the patients analyzed for the miRNA array analysis, we performed transcriptomic profiling for GEM 
analyses. These functional analyses showed, in nonresponders, a decreased enrichment of  about 53% 
of  the selected miR-543 target genes used above and increased enrichment of  genes related to drug and 
xenobiotic metabolism (Supplemental Figure 5). Collectively, these concordant data from stable clones 
and patients indicated that high miR-543 expression could be considered a prognosis marker and might 
be involved in MF progression.
Role of  miR-543 in 3D multicellular spheroid formation. The overexpression of  miR-543 also markedly 
delayed the formation and growth of  3D multicellular tumor spheroids (MCTS) in K562 cells, and to a 
lesser extent in OCI-AML3 cells, on low adherent round-bottom plates (Figure 2B and Supplemental Fig-
ure 6, A and B), showing that this miRNA is involved in tissue structural formation of  hematopoietic cells. 
Moreover, we found that overexpression of  miR-543 in K562 cells caused increase of  the COL1A1/COL3A1 
Table 1. Clinical data of MF patients, cohort 1
Characteristic Responders (nonpalpable spleen) Nonresponders (0%–24% spleen reduction) P value
Number of patients 15 12
Median age (range), y 69 (52–79) 66 (43–83) 0.54
Sex
 Female 7 (47%) 2 (17%) 0.11
 Male 8 (53%) 10 (83%)
Cytogenetics
 Abnormal 5 (33%) 4 (33%) 1
 Diploid (normal) 10 (67%) 8 (67%)
Overall response
 Clinical improvement 14 (93%) 4 (33%) 0.0016
 No response 1 (7%) 6 (50%)
 Progressive disease 0 (0%) 2 (17%)
 Median JAK2V617F allele burden (range) 41.7 (0–95.8) 76.25 (0–93.7) 0.19
 Median WBC level (range) 12.5 (3.4–35.6) 17.2 (4.4–70.4) 0.16
 Median hemoglobin level (range) 10.05 (7.6–14.2) 11.25 (8.6–19.4) 0.13
 Median platelet level (range) 277 (110–647) 249.5 (116–812) 0.89
 Median PB BL level (range) 0.5 (0–2) 1 (0–8) 0.29
 Median neutrophil level (range) 74 (14–85) 68.9 (43–83) 0.10
 Median monocyte level (range) 4.5 (0–17) 8 (2–21) 0.15
 Median albumin level (range) 4.25 (3.1–7) 4.2 (3.8–4.5) 0.74
 Median overall survival (range), months 82 (11.6–116.9) 43.8 (10–87.9) 0.1
For categorical data (sex/age/overall response/cytogenetics results), Fisher’s exact test was used to calculate P values; for age at the beginning of the 
therapy as a continuous variable, the Mann-Whitney-Wilcoxon test was used; and to compare overall survival, log-rank test was used. WBC, white blood 
cells; PB BL, peripheral blood blasts.
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mRNA ratio (Figure 2C), which is a key characteristic in lung (42) and liver (43) fibrosis. Both genes encode 
the collagen found in extensible connective tissues, being involved in tissue structural formation (44, 45).
miR-543 levels are increased by ruxolitinib and by JAK2V617F mutation. To evaluate whether ruxolitinib treat-
ment affects the expression of  miR-543, we stimulated with this drug the wild-type K562 and OCI-AML3 
cells and the respective isogenic stable clones overexpressing miR-543, as well as the J53Z1 erythroid cells 
isolated from the JAK2V617F p53–/– mouse (46). We found that ruxolitinib treatment induced significantly 
higher expression levels of  miR-543 in cells with already overexpressed miR-543 and in J53Z1 cells con-
taining JAK2V617F mutation (Figure 3, A and B).
Figure 1. miRNA expression profiles in BM of MF patients differ according to ruxolitinib treatment responsiveness, specifically for miR-543 levels. (A) Heat-
map displaying the microRNAs most differently expressed in nonresponders (0%–24% spleen size reduction after ruxolitinib treatment; n = 7) compared with 
responders (100% or complete elimination of palpable splenomegaly after ruxolitinib treatment; n = 7). Color key represents normalized expression values, where, 
for each row, red represents the maximum expression value and green the lowest. (B) Differential expression of miR-543 according to responsiveness to ruxolitinib 
treatment was validated by RT-qPCR in the same cohort of patients (cohort 1). (C) miRNA network analysis of the miRNA array profile from responders (n = 7) and 
nonresponders (n = 7). (D) Differential expression of miR-543 was further measured by RT-qPCR in an independent cohort of healthy controls (n = 9) and untreated 
patients with MF (n = 11) (cohort 2). (E) Differential expression of miR-543 was also measured by RT-qPCR in an independent cohort of healthy controls (n = 7) and 
untreated patients with MF (n = 16) (cohort 3). Nonresponder patients are identified with red triangles and responders with blue circles. Two-tailed t test was used 
to assess statistical significance for B, D, and E. Each dot represents 1 human sample. All experiments were repeated independently 3 times.
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To evaluate the role of  miR-543 in MF in vivo and the possible role of  the JAK2V617F mutation in 
miR-543 regulation, we evaluated the expression of  miR-543 in JAK2V617F-transgenic (JAK2V617F-TG) 
mice that develop age-dependent MF (Figure 4A; mice were 60–70 weeks old with fully developed 
disease) (47, 48). We detected significantly higher expression levels of  the miR-543 in BM cells of  
JAK2V617F-TG mice, compared to the wild-type mice of  the same age (Figure 4B). In the JAK2V617F-TG 
mice of  a younger age (13–22 weeks), suffering from PV, the expression of  miR-543 was inconsistent 
and modest (data not shown), suggesting that miR-543 overexpression may be an MF-specific pheno-
type, as supported also by the patients’ data.
To further determine whether the JAK2V617F mutation is involved in the regulation of  miR-543 expres-
sion, we compared the expression level of  miR-543 in HCD57 erythroleukemia cells containing the 
JAK2V617F mutation (HCD-VF1) with the parental HCD57 cells. We found that the HCD-VF1 cells had 
Figure 2. miR-543 promotes drug metabolism–related 
gene enrichment and disrupts cell sphere formation. 
(A) Gene enrichment analysis in K562 cells overexpress-
ing miR-543. (B) The effect of miR-543 in formation and 
growth of 3D multicellular tumor spheroids (MCTS) was 
monitored at different time points for 7 days (24, 48, 
72, and 168 hours) in K562 cells overexpressing miR-543 
compared with those cells stably transduced with emp-
ty vector. Scale bars: 300 μm. (C) Expression ratio of 
COL1A1/COL3A1 transcripts in K562 cells overexpressing 
miR-543 compared with those cells stably transduced 
with empty vector. GAPDH and 18S levels were used as 
normalizers. Statistical differences were determined 
with 2-tailed t test. All experiments were repeated inde-
pendently 3 times, and representative blots are shown. 
NES, normalized enrichment score.
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significantly higher expression of  miR-543 in comparison with the HCD57 parental cells, supporting the 
connection between the presence of  JAK2V617F mutation and the high expression of  miR-543 (Figure 4C).
Activation of  STAT3 induces miR-543 expression through promoter binding. We decided to investigate whether 
JAK2V617F mutation may control miR-543 expression. Because STAT3 is a transcription factor that JAK2 acti-
vates (49, 50), we investigated the existence of  STAT3 binding sites in the surrounding genomic regions of  
miR-543. miR-543 is located at chr14:101,031,987-101,032,064. This genomic region is enriched for several 
miRNAs; however, no host genes have been annotated for miR-543 (UCSC Genome Browser on Human 
Dec. 2013, GRCh38/hg38). In silico analysis of  RNA-Seq reads from normal tissue and cell lines identified 
potential host gene transcriptional start sites within the genomic region chr14:101,012,000-101,021,000. In 
proximity to this region, 4 putative STAT3 binding sites were located (UCSC Genome Browser, ENCODE 
3). Sequence analysis of  these regions identified 1 STAT3 transcription factor consensus binding site (TTC-
CCGaAA, chr14:101,001,972-101,001,980) (51). From this region, we subcloned a 300-bp fragment con-
taining the consensus site into the promoter region of  a luciferase vector and performed luciferase-based 
reporter gene assay in HEK293 cells. Transient transfection of  the vector containing the STAT3 putative 
binding site induced an increase in the luciferase activity when compared with the empty vector as control 
(Figure 4D). Thus, activation by phosphorylation of  STAT3 through JAK2V617F mutation leads to stimulation 
of  miR-543 expression. To confirm this regulation, we performed 2 sets of  experiments. First, using the 
HCD-VF1 cells containing the JAK2V617F mutation, we found a higher STAT3 and p-STAT3Tyr705 protein 
expression compared with the parental nonmutated cell line (Figure 4E). Second, we examined whether 
STAT3 knockdown can affect expression of  miR-543: in vitro siRNA transfection using STAT3 siRNA or 
control siRNA in HCD-VF1 cells (Figure 4F) significantly reduced the expression of  miR-543 in HCD-VF1 
cells when compared with siRNA control–transfected cells (Figure 4G). Overall, JAK pathway activation by 
JAK2V617F mutation initiates transcription of  miR-543 through STAT3 transcription factor.
Role of  miR-543 in targeting both TET1 and TET2. Out of  the thousands of  predicted mRNA targets 
by multiple algorithms, we selected for further investigation TET1 and TET2 because both proteins have 
been previously reported to have functionally significant roles in the development of  fibrosis (52–54). 
Our functional analysis of  selected miR-543 target genes presented above showed TET1 and TET2 
among the genes with significant decrease in gene enrichment (as identified with arrows in Figure 2A, 
and Supplemental Figure 5, left). Furthermore, loss-of-function mutations in Tet2 account for 5%–17% 
of  myeloproliferative neoplasms (MPNs) (55, 56). Moreover, loss of  Tet2 in combination with JAK2V617F 
expression in MPN mouse models appears to render a competitive advantage to hematopoietic stem 
cells, resulting in a more aggressive disease (57–59). Therefore, we evaluated the expression of  these 
2 proteins by Western blot analysis in BM samples from patients belonging to ruxolitinib treatment 
responder and nonresponder groups (Figure 5A). We also measured the expression of  miR-543 in the PB 
samples from the same patients (Figure 5A) and observed an inverse correlation between the expression 
of  miR-543 and the expression of  the 2 proteins, TET1 and TET2 (88.8% of  the cases; 8/9). All patients 
were positive for the JAK2V617F mutation, and from these 9 patients, 8 adhered to the characteristics of  the 
group they belonged to (nonresponder, high miR-543; responder, low miR-543). This suggests that the 
majority of  patients who do not respond to ruxolitinib therapy have loss of  TET1 and TET2 expression 
potentially via miR-543 upregulation, in addition to having the JAK2V617F driver mutation.
To validate whether miR-543 indeed targets TET1 and TET2 mRNAs, we assessed their protein expres-
sion in K562 and OCI-AML3 cells overexpressing miR-543 (Figure 5, B and C, and Supplemental Figure 
7, A and B) and after inhibition of  miR-543 in SET2 cells (human ET cell line, carrying the JAK2V617F 
mutation with high miR-543 expression) by transient transfection with mirVana miR-543 inhibitor (Sup-
plemental Figure 7C). We observed a clear downregulation of  TET1 in cells overexpressing miR-543 com-
pared with control cells for the K562 clones, but we could not confirm the changes in TET2 protein levels 
(Figure 5B and Supplemental Figure 7A). The downregulation of  both TET1 and TET2 with miR-543 
overexpression was confirmed in OCI-AML3 cells (Figure 5C and Supplemental Figure 7B). Additionally, 
the transient downregulation of  miR-543 in SET2 cells showed inverse correlation between the expression 
of  the miRNA and the 2 proteins, TET1 and TET2 (Supplemental Figure 7D). Because STAT3 can induce 
the transcription of  miR-543 through binding to its promoter, we tested the role of  STAT3 in the miR-543–
promoted changes of  TET1 and TET2 mRNA levels. We specifically assessed the TET1 and TET2 mRNA 
levels in K562 cells with STAT3 knockdown by shRNA with an miR-543 mimic versus control random 
sequence. We found that miR-543 mimic statistically significantly decreased both TET1 and TET2 mRNA 
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levels in K562 cells, whereas after the knockdown of  STAT3 by shRNA, the mimic could not significantly 
decrease TET2 or TET1 mRNA levels (Figure 5D).
To validate the direct interaction between miR-543 and TET1/TET2 mRNAs, we immunoprecipitated 
the RNA bound to Ago2 in transfected HEK293 cells overexpressing miR-543 and in control cells with low 
endogenous miR-543 expression. We detected 5.3- and 4.3-fold more TET1 and TET2 mRNA, respectively, 
bound to the Ago2 protein in the cells with high miR-543 expression, confirming the direct interaction of  
the miRNA with its targets (Figure 5E).
Additionally, we detected lower TET2/miR-543 ratios of  expression (by ISH and IHC, respectively) in 
BM histological samples derived from the JAK2V617F-TG mice (40–70 weeks old) compared with the wild-
type mice (Supplemental Figure 8), which translates into lower TET2 protein expression when correlated 
with high miR-543 expression. We did not observe statistically significant differences in TET1/miR-543 
expression ratios, potentially because of  the limited number of  mouse specimens available for analysis. 
Therefore, the association between miR-543 and TET2 can be validated in an age-dependent JAK2V617F-in-
duced MF mouse model, suggesting a role of  the miR-543/TET2 axis in the development of  MF in vivo.
Epigenetic effects of  miR-543. TET1 and TET2 are dioxygenases responsible for the conversion of  5-meth-
yl cytosine (5-mC) into 5-hydroxymethyl cytosine (5-hmC), thus controlling DNA demethylation (60). 
Considering that the canonical function of  TET1 and TET2 is to regulate DNA methylation, we analyzed 
the levels of  5-mC and 5-hmC DNA in cells with altered miR-543 expression. Overexpression of  miR-543 
in K562 cells led to an increased percentage of  the global 5-mC (genome wide; Figure 6A) but no signifi-
cant changes to the percentage of  5-hmC. Overexpression of  miR-543 in K562 cells also led to an increased 
percentage of  the long noncoding RNA H19 DMR of  5-mC (at the H19-S3 genomic locus), but knock-
down of  TET1 or TET2 did not completely inhibit this miR-543–induced effect (Figure 6A). Therefore, 
this indicates decreased activation of  DNA demethylation pathways. These results suggest that miR-543 
does not primarily affect the hydroxymethylation function of  TET proteins, but their decreased levels are 
causing an enhanced global DNA methylation, which corresponds to reduced transcription of  genes (61).
Recently published data show the indirect role of  TET1 on protein acetylation (e.g., H4K16 acetylation) 
(62). We identified that overexpression of  miR-543 decreased global histone 3 acetylation, supported by a 
significant decrease in the enrichment of  genes related to histone 3 acetylation in K562 cells (Figure 6B). 
Surprisingly, we also found that overexpression of  miR-543 in K562 cells decreased STAT3 acetylation (Fig-
ure 6C and Supplemental Figure 9A), supported by a significant decrease in the enrichment of  STAT3 target 
genes actively transcribed when STAT3 signaling is stimulated (Figure 6D). Accordingly, miR-543 inhibi-
tion in SET2 cells increased the acetylation of  STAT3 (Supplemental Figure 9B). Notably, overexpression of  
miR-543 in the BM cells from patients with MF and in K562 cells showed a decrease in the levels of  acetyl-
ated p53 protein (Supplemental Figure 9, C and D), supported by a significant decrease in the enrichment of  
Figure 3. Ruxolitinib treatment induces increase in miR-543 levels when miR-543 and JAK2V617F mutation are present. (A) 
Expression of miR-543 after treatment with ruxolitinib measured by RT-qPCR in K562 cells and OCI-AML3 cells stably trans-
fected with empty vector (control) or p–miR-543 expression vector. U6 and RNU48 levels were used as normalizers.  
(B) Expression of miR-543 after treatment with ruxolitinib measured by RT-qPCR in J53Z1 cells containing the JAK2V617F muta-
tion. U6 and RNU48 levels were used as normalizers. Comparisons were made using 2-tailed t test or Mann-Whitney-Wilcox-
on nonparametric test. All experiments were repeated independently 3 times, and representative blots are shown.
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genes related to p53 pathway activation (Supplemental Figure 9E). Interestingly, phosphatase and tensin homolog 
(PTEN) protein level, which is known to be decreased in primary MF (63), was decreased in representative 
ruxolitinib-resistant patients with high miRNA-543 levels (Supplemental Figure 10A), yet increased in SET2 
cells upon miR-543 inhibition (Supplemental Figure 10B). These findings were corroborated with enrichment 
analysis of  K562 cells overexpressing miR-543 that showed a significant increase in the enrichment of  genes 
transcriptionally active when PTEN is downregulated (Supplemental Figure 10C). These data suggest that 
overexpressed miR-543 targets proteins (e.g., TET) that may have a global effect on protein acetylation (e.g., 
histone 3, STAT3, and p53) that leads to the development of  MF and resistance to ruxolitinib.
Figure 4. JAK2V617F mutation promotes increase in miR-543 levels. (A) Representative diagram of the JAK2V617F-transgenic mouse model of MF and the 
representative histology slides of the BM tissue. Scale bars: 100 μm. (B) Differential expression of miR-543 measured by RT-qPCR in wild-type control mice 
and in JAK2V617F-transgenic mice. (C) Differential expression of miR-543 measured by RT-qPCR in the HCD57 parental control cells and HCD57 erythroleu-
kemia cells containing the JAK2V617F mutation (HCD-VF1). U6 levels were used as normalizer. (D) Relative luciferase activity in HEK293 cells transiently 
cotransfected with the control vector and miR-543 promoter sequence with putative STAT3 binding site. (E) Expression levels of STAT3 and p-STAT3 
Tyr705 were determined by Western blot analysis in HCD57 and HCD-VF1 cells. β-Actin was used as a loading control. (F) Expression levels of STAT3 and 
p-STAT3 Tyr705 were determined by Western blot analysis in HCD-VF1 cells in which STAT3 was silenced by siRNA. β-Actin was used as a loading control. 
(G) Silencing of STAT3 in HCD-VF1 erythroleukemia cells led to decreased miR-543 expression levels as assessed by RT-qPCR. Two-tailed t test was used to 
determine statistical significance for B and D. Mann-Whitney-Wilcoxon nonparametric test was used for C and E. Each dot represents 1 animal. All experi-
ments were performed independently 3 times, and representative blots are shown.
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Discussion
Ruxolitinib improves spleen size, symptoms, and overall prognosis in many patients with MF but 
to different extents and for different durations. In this study, we generated differential miRNA pro-
files, showing increased (e.g., miR-543, miR-382) and decreased (e.g., miR-182, miR-183) miRNAs 
in patients with MF who did not respond to ruxolitinib treatment. In parallel with our study, other 
Figure 5. TET1 and TET2 are direct targets of miR-543. (A) Top: Western blot analysis of TET1 and TET2 proteins in BM samples from patients with MF pos-
itive for the JAK2V617F mutation who responded to ruxolitinib treatment (complete elimination of palpable splenomegaly, low miR-543) or did not respond to 
ruxolitinib treatment (0%–24% spleen size reduction, high miR-543). GAPDH (for TET1) or β-actin (for TET2) protein levels were used as normalizers. Bottom: 
Expression levels of miR-543 in the peripheral blood (PB) samples derived from the same patients. Relative expression of miR-543 was measured by RT-qPCR 
and normalized to U6 and RNU48 levels. (B) Representative Western blot analysis of TET1 and TET2 proteins in K562 cells stably transduced with empty vector 
(control) or p–miR-543 expression vector. GAPDH or β-actin protein levels were used as normalizers. Relative expression of miR-543 measured by RT-qPCR and 
normalized to U6 and RNU48 levels (n = 3; bottom). (C) Representative Western blot analysis of TET1 and TET2 proteins in OCI-AML3 cells stably transduced 
with empty vector (control) or p–miR-543 expression vector. Vinculin or β-actin protein levels were used as normalizers. Relative expression of miR-543 mea-
sured by RT-qPCR and normalized to U6 and RNU48 levels (n = 3; bottom). (D) Expression of TET1 or TET2 in K562 cells stably transduced with STAT3 shRNA or 
control shRNA treated with ruxolitinib after being transiently cotransfected with the miR-543 mimic or control miRNA (scramble mimic). Results presented as 
relative mRNA levels relative to the geometric mean of the 2 normalizers: β-actin and GAPDH. (E) Levels of TET1 and TET2 mRNAs bound to the Ago2 complex 
were pulled down with IgG or anti-Ago2 antibody from HEK293 cells transiently transfected with empty vector (control) or with p–miR-543 expression vector. 
Two-tailed t test was used to assess statistical significance for B and C. Mann-Whitney-Wilcoxon nonparametric test was used for D. All experiments were 
performed independently 2 or 3 times, and representative blots are shown. Ago2, protein argonaute-2; RIP, RNA immunoprecipitation; NS, not significant.
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groups showed that miR-543 is deregulated in MF granulocytes (64) and in PB CD34+ cells (40), vali-
dating the importance of  miR-543 in the pathophysiology of  MF. Collectively, our results demonstrate 
that increased levels of  miR-543 correlate with ruxolitinib treatment “resistance” in patients with MF 
by promoting genes related to ruxolitinib metabolism (e.g., CYP3A4) and by directly targeting the 
TET1 and TET2 transcripts. This regulatory axis was found in the JAK2V617F-TG MF mouse model. 
Somatic mutations in TET2 have been described in about 19%, 12%, 24%, and 22% of  patients with 
Figure 6. miR-543 leads to decreased protein acetylation. (A) Percentage of overall 5-mC methylation levels in K562 
cells stably transduced with empty vector (control) or p–miR-543 expression vector. Percentage of H19 differential-
ly methylated region (DMR) 5-mC methylation levels in K562 cells stably transduced with empty vector (control) or 
p–miR-543 expression vector after being transiently transfected with TET1 or TET2 siRNA. (B) Percentage of overall 
histone 3 (H3) acetylation levels in K562 cells stably transduced with empty vector (control) or p–miR-543 expression 
vector. Gene enrichment analysis of genes related to H3 acetylation in K562 cells overexpressing miR-543. (C) Repre-
sentative Western blot analysis of acetylated STAT3 protein in K562 parental cells and stably transduced with empty 
vector (control) or p–miR-543 expression vector. β-Actin protein levels were used as normalizer. (D) Gene enrichment 
analysis of genes upregulated by STAT3 pathway activation in K562 cells overexpressing miR-543. Two-tailed t test or 
Mann-Whitney-Wilcoxon nonparametric test was used to assess statistical significance for A and B. All experiments 
were repeated independently 3 times, and representative blots are shown.
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myelodysplastic syndromes, myeloproliferative disorders, secondary acute myeloid leukemia (AML), 
and chronic myelomonocytic leukemia, respectively (65). Here we show that patients with MF who 
do not respond well to ruxolitinib therapy have high levels of  miR-543. This miR-543–mediated effect 
also correlates with the downstream effects that show decreases in protein levels of  acetylated STAT3, 
PTEN, acetylated p53, and acetylated histone-3. PTEN is known to be decreased in MF (63).
Interestingly, our results showed that constant activation of  the JAK2/STAT3 signaling pathway by 
the JAK2V617F mutation induces an increase in miR-543 expression. Genomic screening of  the DNA region 
upstream of  the miR-543 host gene shows a STAT3 element, which suggests a direct role of  STAT3 in 
regulating miR-543 expression. We found that phosphorylation of  STAT3 by mutant JAK2 can control 
miR-543 expression epigenetically; however, inhibition of  JAK2/STAT3 signaling by ruxolitinib can fur-
ther induce miR-543 expression levels when miR-543 is already overexpressed. These observations, with 
unpublished data from our group showing that the upstream region of  the miR-543 host gene also contains 
several other DNA elements for the binding of  downstream effector transcription factors (e.g., ATFs, FOS/
JUN) from other oncogenic signaling pathways (e.g., PI3K/AKT), strongly suggest that the regulation of  
miR-543 expression is targeted by multiple signaling pathways related to MF (Figure 7). Further research is 
needed to describe in detail the molecular regulation of  miR-543 expression. However, the main scope of  
this work was to describe the role of  miR-543 in the resistance to ruxolitinib treatment in MF.
In the K562 cells overexpressing miR-543, we observed decreased STAT3 acetylation, which would decrease 
STAT3 signaling pathway activation. This decrease in STAT3 acetylation was corroborated with the decrease 
in the enrichment of target genes actively transcribed by STAT3. This suggests that the miR-543–promoted 
decrease in activation of the STAT3 downstream pathway may reduce the magnitude of the effect of ruxolitinib 
treatment in the inhibition of the signaling activation. In addition to the decrease in the magnitude of the intend-
ed molecular effect of ruxolitinib, the miR-543 can induce the enrichment of transcription of genes related to 
drug and xenobiotic metabolism. Therefore, miR-543 can decrease the ruxolitinib effect and half-life, resulting in 
an overall lack of the expected systemic responses (e.g., decrease in palpable splenomegaly).
Recently, it has been shown that TET1 can activate the transcription and expression of  PTEN by direct 
binding to its promoter region, leading to demethylation of  CpG islands (66). Moreover, in silico analysis 
demonstrated that miR-543 is predicted to target PTEN, and PTEN is known to be downregulated in prima-
ry MF (41, 63). There is a suggested crosstalk of  the AKT signaling pathway linking PTEN to the hypoxia 
response and to the cAMP-related calcium-linked cellular processes (63). Additionally, it has been shown 
that TET1 has a role in protein acetylation (e.g., H4K16 acetylation) (62). Other groups have shown that 
miR-543 can suppress colorectal cancer growth by targeting KRAS and metastasis by targeting MTA1 and 
HMGA2 (67), and it can promote gastric cancer cell proliferation by targeting SIRT1 (68), which is a deacety-
lase of  tumor protein p53 (TP53). Here we demonstrated that miR-543 induces decreased levels of  TET1, 
correlating with decreased protein acetylation (e.g., acetylated histone 3, acetylated STAT3, and acetylated 
TP53 protein levels). Recently, Liu et al. investigated the involvement of  miR-543 in 5-fluorouracil (5-FU) 
resistance in colon cancer cells and showed that downregulation of  miR-543 significantly increased the 
sensitivity of  5-FU through suppressing the PTEN/PI3K/AKT signaling pathway in colorectal cancer cells 
(69). We also showed the negative correlation between miR-543 expression and TET1 and TET2 protein 
levels, demonstrating that TET1/2 are targeted directly by miR-543. However, the downregulation of  both 
TET proteins in K563 and OCI-AML3 cells overexpressing miR-543 was not simultaneously observed. 
Our results suggested that this is most probably due to the presence of  different mutations in epigenetic 
modifiers or cancer drivers between the OCI-AML3 and K562 cell lines (Supplemental Tables 8 and 9). 
OCI-AML3 cells are DNMT3A mutated (DNMT3AR882C) while K562 cells are wild-type. In vitro experi-
ments indicate that the DNMT3AR882C mutation acts in a dominant negative manner to disrupt the de novo 
methyltransferase activity of  wild-type homotetramers (70). AML patient BM harboring DNMT3AR882C 
mutations was similarly demonstrated to be hypomethylated when compared with patients with wild-type 
DNMT3A (71). These aforementioned studies also indicated that non-DNMT3AR882C mutations may act in 
a functionally distinct manner from DNMT3AR882C mutations. Independent prognostic outcomes and treat-
ment protocols may need to be considered for these 2 classes of  DNMT3A mutations.
The limitation of  the research work presented here is the small number of  patients treated with rux-
olitinib. We only focused on 2 very different groups — that is, the complete responders (100% spleen size 
reduction) and the nonresponders (0%–24% spleen size reduction) to ruxolitinib treatment. We rationalized 
that by analyzing the “exceptional” responders and the worst responders, we would be able to identify the 
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most important miRNAs from the many differentially expressed ones. Because of  the limited amount of  
material and variable quality of  RNA from clinical samples, we could ultimately use only 7 patient samples 
per group that preserved the RNA quality suitable for further miRNA array profile and protein analyses. 
However, using the data from patients, in vitro models, and an in vivo TG mouse model, our study provides 
a global overview showing the role of  specific miRNAs, such as miR-543, involved in the transcriptional and 
posttranscriptional dysregulations of  genes that are usually found mutated in patients with MF. In conclu-
sion, we propose miR-543 as a potentially novel biomarker for MF patients with a high risk of  resistance to 
ruxolitinib and as a potential specific target for RNA-based therapeutics.
Methods
Patients and sample collection. BM samples used for miRNA profiling were collected from patients with MF recruit-
ed at the Department of Leukemia at The University of Texas MD Anderson Cancer Center (UT-MDACC) and 
at the Department of Leukemia at the University of Medicine and Pharmacy in Cluj-Napoca (UMF Cluj-Na-
poca, Romania). There were 107 MF patients recruited at UT-MDACC (34, 35, 72, 73). Before the treatment 
regimen, BM cells were collected and stored for research purposes (baseline samples). Spleen reduction was used 
as the main measure of therapy response. This study focused on 2 subgroups, those with 0%–24% spleen size 
reduction and no clinical improvement (representing the nonresponders to ruxolitinib treatment, n = 12) and 
those with 100% spleen size reduction (representing the responders, n = 15), accounting for 27 patients analyzed. 
PB samples for protein analysis were also collected from these patients. Control samples from healthy control 
individuals were obtained from external companies in the United States and Romania.
RNA extraction and miRNA and mRNA expression analyses. Total RNA was extracted from BM aspirates 
and PB samples of  patients with MF, as well as cell lines using TRIzol (Invitrogen, Thermo Fisher Scientif-
ic) by following the manufacturer’s protocol as has been previously described (74, 75).
RNA samples extracted from BM aspirates of  patients with MF were analyzed using an Affymetrix 
GeneChip miRNA 3.0 Array. RNA samples extracted from cell lines’ stable clones were analyzed using 
an Affymetrix GeneChip Clariom S array, human. All microarray data are available at the National Cen-
ter for Biotechnology Information’s Gene Expression Omnibus database under the accession number 
GSE142240. The CEL files generated from Affymetrix DNA microarray image analysis software were 
processed through Transcriptome Analysis Console 4.0, which normalizes (and applies the log2 function 
to) array signals using a robust multiarray averaging algorithm. Differential expression of  miRNAs and 
mRNAs in comparative analysis was determined by a fold change in absolute value equal or greater to 
1.1, a P value obtained from the moderated t-statistic from LIMMA package less than 0.05, and a false 
discovery rate less than 0.1. To support visual exploration of  the miRNA data, a heatmap was generated 
using the heatmap.2 function of  gplots library. Gene set enrichment analysis (GSEA) of  differentially 
expressed genes was performed using GSEA software from Broad Institute.
For RT-qPCR validation of  the miRNA expression analysis, 10 ng of  total RNA was reverse-tran-
scribed and amplified using the TaqMan miRNA Reverse Kit (Applied Biosystems, Thermo Fisher Scien-
tific) with primers/probes specific for each miRNA. RT-qPCR was performed using the synthesized cDNA 
and SsoFast Probes SuperMix (Bio-Rad Laboratories) as previously described (76–78). Each amplification 
was performed in triplicate, where Ct values beyond the upper limit of  the measuring system were input as 
40 (78). miRNA expression was normalized by the ΔCt method, for samples with a Ct less than 40, using 
the small nuclear RNA U6 and the small nucleolar RNA U48 as reference genes (78). For mRNA analysis, 
cDNA was synthesized from 1 μg of  isolated RNA using a High-Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Thermo Fisher Scientific) according to the manufacturer’s instructions. All gene 
expression primers were purchased commercially from Thermo Fisher Scientific. mRNA expression data 
were normalized to GAPDH and 18S.
Generating miRNA networks. We used the correlation coefficient method to build miRNA networks (38, 
39, 79). Briefly, we used the normalized microarray level of  the 23 differentially expressed miRNAs to build 
a correlation matrix of  23 elements for each of  the 2 patient groups. The existence of  an edge between 2 
miRNA nodes depends on the threshold value. As in our previous publication, we chose a high threshold 
value, a Pearson’s correlation r of  ±0.8 (38), which corresponds to a statistically significant P value of  
0.027. The value of  this threshold determines whether an edge exists between 2 miRNA nodes. We selected 
the miRNA pairs from the matrix that correlated above the threshold and drew a line between the corre-
sponding nodes of  the network. We constructed a differential miRNA network for each patient cohort. 
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To check whether there were any statistical differences between the numbers of  edges of  the 2 networks, 
we calculated the node connectivity of  each node and used a paired Wilcoxon’s test to evaluate statistical 
difference between the 2 networks.
Animal model. JAK2V617F-TG mice were generated by expressing human JAK2V617F in the hematopoi-
etic system under the control of  the vav-1 promoter (36). These mice have been crossed with wild-type 
C57BL/6 mice for over 10 generations. Homozygous line A JAK2V617F mice were used in this study, and 
wild-type C57BL/6 mice were used as controls as previously described (80, 81).
RIP. For the TET1 and TET2 mRNA analysis, the RNA bound to the Ago2 protein was immuno-
precipitated with the Magna RIP kit (MilliporeSigma) following the manufacturer’s protocol. Briefly, 
15,000,000 cells overexpressing either scramble (scr) control or miR-543 were prepared in RIP lysis buf-
fer, and the RNA-protein complexes were immunoprecipitated using anti-Ago2 and normal rabbit IgG 
(as control) antibodies. RNA was purified using the phenol-chloroform-isoamyl alcohol method and fur-
ther used for cDNA synthesis using random hexamers, deoxynucleoside triphosphates, and SuperScript 
III Reverse Transcriptase (all from Invitrogen, Thermo Fisher Scientific). RT-qPCR was performed using 
the synthesized cDNA and primers specific for TET1 (forward: 5′-GCCCCAAGTCAGAATCCATG-3′; 
reverse: 5′ TCCACTTCTCCACCTCGATG-3′) and TET2 (forward: 5′-GAGCAGGTCCTAATGTGG-
CA-3′; reverse: 5′-TTCTGCGAACCACCCACTTA-3′). The fold enrichment was calculated using the 2–ΔCt 
method, normalized to the input and to the IgG control.
Identification of  miR-543 targets. To predict in silico hsa-miRNA-543 target genes and predicted bind-
ing sites, we retrieved experimentally validated miRNA-mRNA interactions from miRTarBase database 
(http://mirtarbase.mbc.nctu.edu.tw), TarBase database version 8 (http://carolina.imis.athena-innova-
tion.gr/diana_tools/web/index.php?r=tarbasev8%2Findex), and miRecords database (http://c1.accu-
rascience.com/miRecords/). We also retrieved miRNA-target interaction information from the miR-
Walk2.0 database (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk2) that hosts miRNA-target 
Figure 7. Proposed model of the role of miR-543 in MF.
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predictions from 12 programs. We selected targets that were predicted by at least 6 algorithms (half  
the total number of  programs checked) or experimentally validated (regardless of  the target prediction 
results). The selected target genes were used as a gene set for GSEA of  transcriptomic data from K562 
stable clones overexpressing miR-543 in comparison with those with empty vector (see Figure 2A).
Cell culture, transduction, and transfection. The leukemia cancer cell lines K562 and OCI-AML3 (82) and 
derivative clones were cultured in RPMI cell culture medium supplemented with 10% fetal bovine serum 
(FBS), 1% penicillin/streptomycin, 1% nonessential amino acids, and 1% HEPES buffer. SET2 cells were 
maintained in RPMI medium with 20% FBS. J53Z1, HCD-57, and HCD-VF1 cell lines were maintained 
as previously described (46, 83). HEK293 cells were grown in DMEM, supplemented with 10% FBS. All 
cell cultures were maintained in a humidified environment at 37°C and 5% CO2 and passaged no more than 
10 times before the experiments. Before the start of  the in vitro experiments, cells were authenticated by 
MDACC Characterized Cell Line Core Facility and were tested for mycoplasma contamination.
K562 and OCI-AML3 cells overexpressing hsa-miR-543 were generated using the pMIRNA1 lenti-
viral vector (System Bioscience) by following the manufacturer’s protocol (see Supplemental Methods). 
Briefly, the hsa-miR-543 precursor was subcloned into the vector, and 293FT cells were transduced with 
either the pMIRNA-543 vector or the pMIRNA empty vector (control). The virus in the supernatant 
was collected 48 hours later. K562 and OCI-AML3 cells were infected with the virus, and the GFP+ 
cells were sorted by FACS. Inhibition of  miR-543 expression in SET2 cells was performed by cell trans-
fection with 100 nM of  anti–miR-543 mirVana miRNA inhibitor or with 100 nM scr negative control 
(all from Ambion, Life Technologies), using Lipofectamine 2000 reagent (Invitrogen, Thermo Fisher 
Scientific), according to the manufacturer’s protocol. Knockdown of  STAT3 in HCD-VF1 cells was 
performed by cell transfection with 50 nM of  STAT3 siRNA (MilliporeSigma) or with 50 nM negative 
control (MilliporeSigma).
3D MCTS formation. K562 and OCI-AML3 cells were seeded in a 96-well low adherence round-bottom 
plate (Greiner Bio One) in 100 μL of  medium at 10,000 cells per well. Images of  the MCTS were captured 
using the IN Cell 6000 imager (GE Healthcare) at different time points (24, 48, 72, and 168 hours) to mon-
itor their formation and growth. Medium was changed every 72 hours.
DNA isolation, DNA methylation, and histone 3 acetylation measurements. After transfection, DNA from 
cell lines was extracted using the Quick-DNA Miniprep Kit (Zymo Research). For DNA methylation 
measurements, cell pellets were harvested 24 hours after transfection as described above. Then, the 
DNA samples were processed and DNA methylation or hydroxymethylation was determined using 
the MethylFlash Methylated Quantification Kit or MethylFlash Hydroxymethylated DNA Quantifi-
cation Kit following the manufacturer’s recommendation (Epigentek). DNA methylation analysis of  
the genome was also assessed by pyrosequencing methylation analysis at UT-MDACC Epigenomics 
Profiling Core Facility. For global histone H3 acetylation measurements, cell pellets were harvested 24 
hours after transfections as described above. Then, the DNA samples were processed and global histone 
H3 acetylation was determined using the EpiQuik Global Histone H3 Acetylation Assay Kit following 
the manufacturer’s recommendations (Epigentek).
Mutation screening of  genes involved in epigenetic regulation (TET1, TET2, IDH1, IDH2, and 
DNMT3A) and JAK2 was performed in DNA from OCI-AML3, SET2, and K562 cell lines using a stan-
dard PCR amplification protocol followed by Sanger sequencing. Sequencing was performed on an ABI 
Sequencer 3730, and the data were analyzed using SeqMan Pro (DNASTAR, Lasergene). Primer sequenc-
es are shown in Supplemental Methods.
Protein analysis. Protein analyses were performed using lysates from whole-cell pellet samples in 
radioimmunoprecipitation assay buffer containing protease and phosphatase inhibitor cocktails (Milli-
poreSigma), as previously described (75). Protein concentration was quantified by the Bradford assay 
(Bio-Rad), and equal amounts were loaded on 4%–20% (or 4%–15% for TET2 hybridization) acrylamide 
Criterion TGX precast gels (Bio-Rad) for Western blot analysis. Resolved proteins were semidry-trans-
ferred to nitrocellulose membranes, which were then probed overnight with the following anti-human 
primary antibodies: TET1 (MilliporeSigma, SAB2700730; mouse monoclonal, 1:1,000), TET2 (Cell 
Signaling Technology, 4510S; rabbit polyclonal, 1:1,000), acetyl-TP53 (Cell Signaling Technology, 
2570; rabbit polyclonal, 1:1,000), acetyl-STAT3 (Cell Signaling Technology, 2523; rabbit polyclonal, 
1:1,000), STAT3 (Cell Signaling Technology, 9139; mouse monoclonal, 1:3,000), p-STAT3 (Tyr705) 
(Cell Signaling Technology, 9145; rabbit monoclonal, 1:1,000), GAPDH (Santa Cruz Biotechnology, 
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SC51905; mouse monoclonal, 1:1,000), β-actin (MilliporeSigma, A2066; rabbit polyclonal, 1:10,000; or 
MilliporeSigma, A9357, mouse polyclonal, 1:4000), and vinculin (Santa Cruz Biotechnology, SC7649; 
goat polyclonal, 1:1,000). Membranes were then incubated with appropriate HRP-conjugated second-
ary antibody, followed by incubation with ECL detection substrate (GE Healthcare) or SuperSignal 
West Femto substrate (Thermo Fisher Scientific), and the chemoluminescent signal was detected with 
autoradiographic paper.
ISH and IHC analysis. The formalin-fixed, paraffin-embedded tissue sections were dewaxed in xylene and 
rehydrated through an ethanol dilution series. Tissue sections were digested with 5 μg/mL proteinase K for 10 
minutes at room temperature, then loaded onto Ventana Discovery Ultra for ISH analysis. The tissue slides 
were incubated with double digoxigenin–labeled mercury LNA microRNA probe (Exiqon) for 2 hours at 
55°C. Slides were treated with 3% H2O2 to inactivate endogenous peroxidase activity and blocked with 5% 
bovine serum albumin in PBS (w/v), followed by primary and secondary antibody incubation in 1% bovine 
serum albumin (w/v) with 0.1% Tween-20 (v/v) in PBS) and washes in 0.01% Tween-20 (v/v) in PBS. Tyra-
mine-conjugated fluorochrome was applied to the slide, and the tyramide signal amplification (TSA) reaction 
was allowed to proceed for 10–30 minutes. For the detection of protein, the tissue slides were incubated with 
primary antibody for 1 hour at 37°C after deparaffinization, and the secondary antibody (OmniMap anti-Rb 
HRP, Ventana, 760-4311) incubation and TSA reaction followed the same protocol. Fluorescent images were 
analyzed using LAS v4.3 software (Leica).
Statistics. Statistical analysis and graphical representation were performed with GraphPad Prism (version 
7.01). P values less than 0.05 were considered significant. The distributions of the data are displayed in box-
and-whisker plots showing all points and outlying the minimum, first quartile, median, third quartile, and max-
imum values in duplicate or triplicate experiments. Shapiro-Wilk normality test was performed for each group 
to assess whether data were normally distributed. For normally distributed data, 2-tailed t test was used to com-
pare mean values between different groups. When 1 of the groups did not pass the normality test, Mann-Whit-
ney-Wilcoxon nonparametric test was used to assess statistical differences between the different groups.
Study approval. All clinical data and human samples were obtained from participants who had giv-
en written informed consent, according to protocols approved by the Oncology Institute Ion Chiricuta 
Ethics Committee in accordance with the Declaration of  Helsinki and UT-MDACC Institutional Review 
Board. All animal experiments were conducted in accordance with American Association for Laboratory 
Animal Science regulations and with the approval of  Institutional Animal Care & Use Committees from 
UT-MDACC and the University of  Oklahoma Health Sciences Center.
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